Phargentis signs early partnership with Euro-wide generic pharma company for its third major generic product
(March 23, 2022) Phargentis has entered an early license agreement with a major European pharmaceutical company over the third major generic inhaled therapy that Phargentis is developing - an interchangeable version of Fostair® (beclomethasone / formoterol), a best-selling pMDI asthma and COPD treatment with a 2020 turnover of 529 MUSD in Europe. Phargentis CEO Andrea…
Phargentis achieves positive results in pilot PK study of its new generic version of COPD treatment indacaterol/glycopyrronium plus DPI device
Phargentis announces another important milestone in achieving positive results in the clinical pilot study of ‘Glide’, its new generic version of COPD treatment indacaterol/glycopyrronium plus Dry Powder Inhaler. The clinical study demonstrated good comparability between ‘Glide’ and originator product Ultibro®Breezhaler®. Phargentis will now proceed to the next pivotal phase of development, on schedule. Global sales…
Phargentis begins clinical development of early-entry generic version of COPD treatment indacaterol/glycopyrronium and DPI device
(16 December, 2021) Phargentis has begun clinical development of its capsule based DPI (Dry Powder Inhaler) product containing indacaterol/glycopyrronium (85 mcg/43 mcg) designed to be an early-entry, fully interchangeable generic version of the global COPD treatment Ultibro®Breezhaler®. Sales of the treatment exceed 500 MUSD a year. The news follows the recent announcement of the company’s…
First European sales of generic Tiotropium bromide 18 µg DPI, developed by Phargentis
(November 10, 2021) Tiotropium bromide 18 µg Dry Powder Inhaler developed by Phargentis has been launched in Europe. It is the first generic product approved in the EU with precisely the same strength and same delivered dose as Spiriva®Handihaler®, the global first-line treatment for COPD. This generic equivalent has been delivered to the UK, Norway,…
Generic Tiotropium bromide 18 µg DPI, developed by Phargentis, receives approval in 28 European countries
(November 11, 2021) Tiotropium bromide 18 µg Dry Powder Inhaler is the first generic product approved in the EU with the same strength and same delivered dose as Spiriva®Handihaler®, the global first line treatment for COPD – enabling possibility for full reimbursement across the European Union and other key international markets. Developed by Phargentis, it…
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional
Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes.The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
